re: recent investment report for novogen attn gerr
Gerry, are you around?
What are your thoughts on the projections in this report. Looks conservative given they have done the numbers on only two cancer types and assumed a profit margin of 10% (compared to royalty rates up to 40% for similar drugs), a cost of $10000 p.a. (compared to other anti-cancer drugs charging much more) and didn't take into account any large one off payment in a licence deal. This payment could be quite significant when compared to payments to Imclone for it's Erbitux drug of $2bn approx $20/share for Novogen.
Anyhow, good to see analysts finally seeing the potential in novogen i.e. the best drug of it's kind out there and a low market cap.
NRT Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
